头颈癌自适应数字剂量绘画与非自适应放疗的疾病控制及晚期毒性:一项随机对照2期试验
这项2中心随机对照2期试验将95例非转移性头颈癌患者按1:1分配至自适应18F-FDG-PET体素强度数字剂量绘画(A-DPBN)或非自适应标准调强放疗(S-IMRT)。A-DPBN组1年和2年局部控制率分别为91%和88%,优于S--IMRT组的78%和75%(HR 3.13,95%CI 1.13-8.71,P=.021);区域控制、总生存及≥3级晚期毒性两组相当。
要点
- A-DPBN较S-IMRT显著改善1年和2年局部控制(91%/88% vs 78%/75%,HR 3.13,P=.021)。
- 两组区域控制、总生存及≥3级晚期毒性无显著差异(36% vs 20%,P=.1)。
- 持续吸烟者≥3级晚期黏膜溃疡更多(29% vs 3%,P=.005),与治疗臂无关。
核心结论
- A-DPBN较S-IMRT显著改善头颈癌1年和2年局部控制。
- 作者认为该结果支持在多中心3期试验中进一步探索。
- 作者指出,由于对持续吸烟者剂量提升相关晚期黏膜溃疡的担忧,招募足够样本量将具有挑战性。
研究设计与样本
- 2中心随机对照2期试验,按1:1分配患者接受A-DPBN或S-IMRT(±化疗)。
- 纳入标准:非转移性口腔、口咽/下咽或喉头颈癌需放(化)疗;T1-4N0-3(除外T1-2N0声门癌);KPS≥70;≥18岁;签署知情同意。
- 共95例患者随机分组(A-DPBN组47例,S-IMRT组48例),中位随访31个月(IQR 14-48个月)。
- 主要终点为1年局部控制率和区域控制率。
主要发现
- A-DPBN组1年和2年局部控制率分别为91%和88%,S-IMRT组分别为78%和75%(HR 3.13,95%CI 1.13-8.71,P=.021)。
- 两组区域控制和总生存相当。
- 两组总体≥3级晚期毒性分别为36%和20%(P=.1)。
- 活跃吸烟者≥3级晚期黏膜溃疡发生率29% vs 3%(P=.005),饮酒者33% vs 13%(P=.02),与治疗臂无关。
- A-DPBN组中,诊断时吸烟者发生≥3级黏膜溃疡显著更多(46% vs 12%,P=.005),≥4级也更多(29% vs 8%,P=.048)。
关键数值与推荐
- A-DPBN剂量处方在研究过程中根据绝对剂量-体积限值(≤1.75 cm3可接受>84 Gy且归一化等效生物剂量>96 Gy)分两步进行同期自适应调整,作为安全措施,此前4/7例A-DPBN患者发生≥G3黏膜溃疡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,由于对持续吸烟者剂量提升相关晚期黏膜溃疡的担忧,招募足够样本量进行3期试验将具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Local recurrence remains the main cause of death in stage III-IV nonmetastatic head and neck cancer (HNC), with relapse-prone regions within high 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)-signal gross tumor volume. We investigated if dose escalation within this subvolume combined with a 3-phase treatment adaptation could increase local (LC) and regional (RC) control at equal or minimized radiation-induced toxicity, by comparing adaptive 18F-FDG-PET voxel intensity-based dose painting by numbers (A-DPBN) with nonadaptive standard intensity modulated radiation therapy (S-IMRT). METHODS AND MATERIALS: This 2-center randomized controlled phase 2 trial assigned (1:1) patients to receive A-DPBN or S-IMRT (+/-chemotherapy). Eligibility: nonmetastatic HNC of oral cavity, oro-/hypopharynx, or larynx, needing radio(chemo)therapy; T1-4N0-3 (exception: T1-2N0 glottic); KPS ≥ 70; ≥18 years; and informed consent. PRIMARY OUTCOMES: 1-year LC and RC. The dose prescription for A-DPBN was intercurrently adapted in 2 steps to an absolute dose-volume limit (≤1.75 cm3 can receive >84 Gy and normalized isoeffective dose >96 Gy) as a safety measure during the study course after 4/7 A-DPBN patients developed ≥G3 mucosal ulcers. RESULTS: Ninety-five patients were randomized (A-DPBN, 47; S-IMRT, 48). Median follow-up was 31 months (IQR, 14-48 months); 29 patients died (17 of cancer progression). A-DPBN resulted in superior LC compared with S-IMRT, with 1- and 2-year LC of 91% and 88% versus 78% and 75%, respectively (hazard ratio, 3.13; 95% CI, 1.13-8.71; P = .021). RC and overall survival were comparable between arms, as was overall grade (G) ≥3 late toxicity (36% vs 20%; P = .1). More ≥G3 late mucosal ulcers were observed in active smokers (29% vs 3%; P = .005) and alcohol users (33% vs 13%; P = .02), independent of treatment arm. Similarly, in the A-DPBN arm, significantly more patients who smoked at diagnosis developed ≥G3 (46% vs 12%; P = .005) and ≥G4 (29% vs 8%; P = .048) mucosal ulcers. One arterial blowout occurred after a G5 mucosal toxicity. CONCLUSIONS: A-DPBN resulted in superior 1- and 2-year LC for HNC compared with S-IMRT. This supports further exploration in multicenter phase 3 trials. It will, however, be challenging to recruit a substantial patient sample for such trials, as concerns have arisen regarding the association of late mucosal ulcers when escalating the dose in continuing smokers.
引用
- De Bruycker A, De Neve W, Daisne JF, et al. Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387811. doi:10.1016/j.ijrobp.2024.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。